Subscribe to our newsletter
We send newsletters a few times per year with important updates about the ECG247 system, including news, feature changes, ECG training resources, case reports, research projects, and other relevant information. We promise not to overwhelm you with many emails, and we never share your contact details with third parties. The newsletters are intended for healthcare professionals.
Add more ECG strips to the PDF report
It is now possible to add even more ECG strips to the PDF report. Simply click the "Add to report" button under the relevant ECG strips. Expanded PDF report is only available for software license
New Measurement Tools for Heart Rate, HRV, and ECG
We have updated the ECG247 Portal with new and improved interactive measurement tools, making the analysis of heart rhythm recordings even easier. What's new? Flexible calculation of heart rate and heart rate variability: Select
The NORSCREEN Study Confirms ECG247 as an Ideal Solution for At-Home Screening for Atrial Fibrillation
More results from the nationwide NORSCREEN study (50,549 participants) have now been published in the renowned journal Europace. The study concludes that fully digital, site-less screening with ECG247 is a highly effective and
Expanding in Europe and Enhancing User Experience
We are taking another important step towards making continuous heart monitoring accessible to even more people. As part of our European expansion, we are launching the ECG247 app and ECG247 portal in four new languages—while
Monitoring NORSEMAN Participants with ECG247
What happens to the heart during and after the world's toughest triathlon? Researchers from the Norwegian School of Sport Sciences (NIH) and the University of Oslo (UiO) are now monitoring participants in this year’s Norseman
New Study: High Diagnostic Reliability and Efficient Resource Utilization
A new study published in EP Europace demonstrates that ECG247 provides a high level of agreement in the diagnosis of atrial fibrillation. For clinicians, the findings from the NORSCREEN trial signify not only increased diagnostic
